Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 619-621, 2008; 10.1373/clinchem.2007.097998
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Luckenbill, K. N.
Right arrow Articles by Apple, F. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luckenbill, K. N.
Right arrow Articles by Apple, F. S.
(Clinical Chemistry. 2008;54:619-621.)
© 2008 American Association for Clinical Chemistry, Inc.

Letters

Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac Damage

Kristin N. Luckenbill1, Robert H. Christenson2, Allan S. Jaffe3, Johannes Mair4, Jordi Ordonez-Llanos5, Franca Pagani6, Jillian Tate7, Alan H. B. Wu8, Ranka Ler1 and Fred S. Apple1,a

1 Hennepin County Medical Center, University of Minnesota School of Medicine, Minneapolis, MN
2 University of Maryland School of Medicine, Baltimore, MD
3 Mayo Clinic and Mayo College of Medicine, Rochester, MN
4 Department of Internal Medicine, Clinical Division of Cardiology, Innsbruck Medical University, Austria
5 Department of Biochemistry, Hospital de la Santa Creu i Sant Pau and Universitat Autonoma, Barcelona, Spain
6 Laboratorio Analisi Chimico Cliniche, Dipartimento di Medicina di Laboratorio, Azienda Ospedaliera ‘Spedali Civili’, Brescia, Italy
7 Chemical Pathology Department Pathology, Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia, 8 University of California at San Francisco, San Francisco General Hospital, San Francisco, CA

aAddress correspondence to this author at: Hennepin County Medical Center, Clinical Laboratories P4, 701 Park Ave, Minneapolis, MN 55415, Fax 612-904-4229, e-mail apple004@umn.edu

The first 20% of the full text of this article appears below.


To the Editor:

B-type natriuretic peptide (BNP) is a 32 amino acid cardiac-synthesized hormone that reduces blood pressure and increases sodium excretion (1). Following proteolytic cleavage of proBNP, a 108-amino acid precursor, an N-terminal fragment (NT-proBNP) and BNP are released (2). Increased concentrations of BNP and NT-proBNP can be used clinically to monitor heart failure, but a lack of alignment between commercial BNP and NT-proBNP assays (3) can lead to confusion when clinicians or laboratorians compare results measured for the same analyte on different instruments. Some of this confusion arises from variable assay specificity regarding what peptides are being measured. We studied whether (a) BNP assays demonstrated cross-reactivity with NT-proBNP or proBNP, and (b) whether NT-proBNP assays demonstrated cross-reactivity with BNP or proBNP, by using 5 commercial BNP and 3 commercial NT-proBNP assays with 2 BNP, 2 NT-proBNP, and 2 proBNP materials.

The NPs studied were: Peptide . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.